A study found that primary care physician-nephrologist collaboration did not improve kidney or CV outcomes in stage 5 CKD. A study showed similar efficacy and cardiovascular safety between vadadustat and darbepoetin alfa for anemia with CKD. Zachary Kon, MD, CEO and co-founder of ProCure On-Demand, discussed the company's organ recovery and logistics services. Hyperuricemia and gout are predictors of increased prevalence and mortality of cardiac, renal, and metabolic conditions. Elevated glucose uptake in adipose tissue of patients with gout may contribute to CKD progression. We spoke with George Edward Newman, MD, a site principal investigator of the PREVAIL study of felzartamab in IgAN. Kidney transplant recipients with psoriasis have a higher risk for transplant failure. The Kidney Transplant Fast Track intervention improved patients' odds of being waitlisted, a trial found. Kidney transplant candidates and their families often feel responsible but powerless during evaluation, a survey finds. Use of SGLT2i with RAASi is associated with reduced risk for hyperkalemia in the clinical setting, a study found. Kidney Care Partners visited called on Congress to support policies benefitting Americans with kidney disease. AstraZeneca and Aptar Digital Health are partnering on screening algorithms to detect CKD and other conditions. Study results suggest that psychosocial interventions effectively reduce depression symptoms in people with CKD. Meta-analyses reaffirmed cardiovascular and renal benefits of long-acting GLP-1RAs for patients with type 2 diabetes. Variability in eGFR over time is associated with risks of cardiovascular and kidney outcomes and mortality in those with CKD. An observational study shed light on how family medical history may affect chronic kidney disease (CKD) outcomes. A report based on chart data and specialist surveys reveals gaps in treatment for FSGS but optimism about the drug pipeline. The FDA has granted Orphan Drug Designation to veverimer for anti–glomerular basement membrane (anti-GBM) disease. Fibrate use is associated with higher incidence of CKD but lower risk for ESKD and mortality, a study found. Richard Furie, MD, discussed the REGENCY trial of obinutuzumab in systemic lupus erythematosus and lupus nephritis.